A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977
This study is recruiting at 9 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Small Cell Lung Cancer (SCLC)
- Follicular Lymphoma (FL)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Nebraska · 1
- Oncology Hematology West, PC dba Nebraska Cancer Specialists · Omaha, NE
Oklahoma · 2
- OU Health University of Oklahoma Medical Center · Oklahoma City, OK
- Stephenson Cancer Center (chemo location) · Oklahoma City, OK
South Carolina · 2
- Carolina Urologic Research Center · Myrtle Beach, SC
- Parkway Surgery Center · Myrtle Beach, SC
Tennessee · 2
- Sarah Cannon Research Institute - Pharmacy · Nashville, TN
- SCRI Oncology Partners · Nashville, TN
Texas · 2
- NEXT Dallas · Irving, TX
- NEXT Oncology · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.